Meeting
2019 Gastrointestinal Cancers Symposium
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP) following first-line sorafenib: Pooled efficacy and safety in Japanese patients across two global randomized phase III studies (REACH-2 and REACH).
Authors
Masatoshi Kudo
Kindai University Faculty of Medicine, Osaka-Sayama, Japan
Masatoshi Kudo , Takuji Okusaka , Kenta Motomura , Izumi Ohno , Manabu Morimoto , Satoru Seo , Yoshiyuki Wada , Shinpei Sato , Tatsuya Yamashita , Masayuki Furukawa , Takeshi Aramaki , Seijin Nadano , Kazuyoshi Ohkawa , Hirofumi Fujii , Toshihiro Kudo , Junji Furuse , Hiroki Takai , Gosuke Homma , Reigetsu Yoshikawa , Andrew X. Zhu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01140347 (REACH), NCT02435433 (REACH-2)
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 320)
DOI
10.1200/JCO.2019.37.4_suppl.320
Abstract #
320
Poster Bd #
G18
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.
First Author: Shukui Qin
Poster
2016 ASCO Annual Meeting
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2016 Gastrointestinal Cancers Symposium
A randomized, double-blind, placebo-controlled phase III study of ramucirumab versus placebo as second-line treatment in patients with hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib (REACH-2).
First Author: Andrew X. Zhu
Poster
2015 ASCO Annual Meeting
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome (PFO) results from the phase 3 REACH study.
First Author: Ian Chau